Bora CDMO

Executive Summary

Bora Pharmaceuticals is a global contract development and manufacturing organization (CDMO) that offers end-to-end solutions for complex pharmaceutical products, including oral solids, liquids, semi-solids, nasal sprays, ophthalmics, sterile injectables, and biologics. Founded in 2019 and headquartered in San Diego, Bora operates ten cGMP-compliant facilities across the United States, Canada, and Taiwan. The company supplies finished drug products to over 100 countries, serving a diverse client base ranging from emerging biotechs to large pharmaceutical companies. By leveraging its multi-site manufacturing network and deep formulation expertise, Bora aims to accelerate drug development and commercialization for its partners. Bora's growth strategy centers on expanding its manufacturing capacity and service offerings through organic investments and strategic acquisitions. The company has established itself as a reliable partner for both clinical and commercial production, with a particular focus on high-potency compounds and complex dosage forms. As the pharmaceutical outsourcing market continues to expand, Bora is well-positioned to capture increasing demand from drug developers seeking scalable and compliant manufacturing solutions. Its private ownership allows for long-term strategic planning, but also limits public visibility into operational milestones.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major long-term manufacturing agreement with a top-20 pharma company50% success
• TBDCompletion of a capacity expansion project at a key facility (e.g., new sterile injectable line)70% success
• Q4 2026Successful FDA inspection of a facility with no Form 483 observations, reinforcing regulatory standing80% success